The management of RA has improved dramatically with the development of antibody-based drugs against TNF and IL-6 (known as biological disease-modifying antirheumatic drugs, DMARDs) and JAK inhibitors, in addition to methotrexate. Here, IL6 is linked to rheumatoid arthritis.